Navigation Links
Orexigen Therapeutics, Inc. Prices Offering of $100 Million of Convertible Senior Notes
Date:12/3/2013

xigen cautions you that statements included in this press release that are not a description of historical facts are forward‐looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward‐looking statements. These statements are based on the Company's current beliefs and expectations. These forward‐looking statements include statements regarding: the actual terms of the Notes, the completion, timing and size of the proposed private offering and the anticipated use of proceeds from the offering. The inclusion of forward‐looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business. You are cautioned not to place undue reliance on these forward‐looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in Orexigen's Current Report on Form 8-K filed with the Securities and Exchange Commission on December 2, 2013 and its other reports, which are available from the SEC's website (www.sec.gov). All forward‐looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.Orexigen Contact:

Media Contact: McDavid Stilwell

Denise Powell

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
2. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
3. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
6. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
7. Orexigen Therapeutics to Present at Upcoming Conferences
8. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
9. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
10. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Trius Therapeutics, Inc. - TSRX
11. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... On behalf of biotech client GenScript ... Goldman & Spitzer, P.A. (Wilentz) secured a significant jury ... in excess of $10 million. The jury determined that ... that it improperly hired one or more of GenScript,s ... judgment notwithstanding the verdict, a new trial, and remittitur. ...
(Date:2/26/2015)... LA JOLLA, Calif. , Feb. 26, 2015 /PRNewswire/ ... ), a biopharmaceutical company leading the discovery and development ... Kleanthis G. Xanthopoulos , Ph.D., President and Chief Executive ... the Cowen and Company 35 th Annual Healthcare ... EST.  The conference is being held at the Boston ...
(Date:2/26/2015)... 26, 2015 On behalf of biotech ... companies, Wilentz, Goldman & Spitzer, P.A. (Wilentz) ... lawsuit against Genewiz Inc. in excess of $10 million. ... GenScript’s trade secrets, and that it improperly hired one ... an order denying motions for judgment notwithstanding the verdict, ...
(Date:2/26/2015)... PA (PRWEB) February 26, 2015 ... 9 -12, at the Ernest N. Morial Convention ... exhibitors (count as of February 19, 2015) displaying ... in industrial, academic, and government labs. The Exposition ... as, but not limited to, analytical chemistry; drug ...
Breaking Biology Technology:Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Pittcon 2015 Announces Exposition Highlights 2
... Inc. (Pink Sheets: AMHI), http://www.americanhealthchoice.com , a,medical ... Tennessee, is,pleased to announce the first sales of ... imaging camera that detects patterns of abnormality within,the ... prevention and,treatment. , ...
... KVISTGARD, Denmark, November 19 Bavarian Nordic,has invoiced ... USD 25,million as allowed under the RFP-3 contract ... company,s IMVAMUNE(R) smallpox vaccine. This milestone,payment was triggered ... report,from a large Phase II study with IMVAMUNE(R) ...
... Calif., Nov. 19 Arete Therapeutics Inc., ... (s-EH) inhibitors, today announced that it has ... financing. Frazier Healthcare Ventures and Alta,Partners co-led ... existing,investors Burrill & Company, Three Arch Partners, ...
Cached Biology Technology:American HealthChoice Announces the First Sales of the OmniBody Scan 2Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities 2Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing 2
(Date:2/5/2015)... , Jan. 28, 2015 Research and ... the addition of the "Global Biometrics Market ... Regions and Countries " report to their offering. ... Asia-Pacific is anticipated to ... 2015, owing to increasing government spending towards IT ...
(Date:2/5/2015)... , Feb. 3, 2015 Despite a ... from industries such as consumer electronics, automotive, storage ... surface mount technology (SMT) screen printers. Innovations in ... control will push the adoption curve up. Meanwhile, ... steady as glue dispensers are indispensable in the ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... CHAMPAIGN, Ill. University of Illinois chemists have developed ... shoe bombs. It could lead to inexpensive, easy-to-use devices ... Triacetone triperoxide (TATP) is a high-powered explosive that ... attempts. TATP is easy to prepare from readily available ...
... of Adelaide have discovered new cases of herbicide ... serious and costly weeds. For the first time, ... to paraquat, the second most important "knockdown" herbicide used ... Boutsalis and Associate Professor Christopher Preston, from the University,s ...
... State University researchers are hoping their project will reduce ... beaches and additional problems triggered by harmful algal blooms. ... Agency, the MSU team of scientists will work to ... as well as the entire Great Lakes basin. The ...
Cached Biology News:Sniffing out shoe bombs: A new and simple sensor for explosive chemicals 2
... The LUMIstar OPTIMA is a ... is designed for the widest possible ... labels: Reporter gene assays luciferase, ... (luminol, acridinium esters, dioxetanes..) Luminescent ...
... depleted sera are specifically depleted of a ... the depleted protein, the alternative and classical ... therefore ideal for the detection and quantitation ... have been used to assess complement activation ...
... The latest generation of the ... M.I.T. for the iontophoresis of neural ... (HRP) or tritiated amino acids into ... Stoelting. It may also be used ...
... of apoptosis and mitochondrial membrane potential. The ... indication of the initiation of cellular apoptosis. ... collapse in the electrochemical gradient across the ... in the membrane potential (YD). Loss of ...
Biology Products: